• Login
    JavaScript is disabled for your browser. Some features of this site may not work without it.
    Genome-wide association study of response to methotrexate in early rheumatoid arthritis patients 
    •   QMRO Home
    • William Harvey Research Institute
    • Clinical Pharmacology
    • Genome-wide association study of response to methotrexate in early rheumatoid arthritis patients
    •   QMRO Home
    • William Harvey Research Institute
    • Clinical Pharmacology
    • Genome-wide association study of response to methotrexate in early rheumatoid arthritis patients
    ‌
    ‌

    Browse

    All of QMROCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects
    ‌
    ‌

    Administrators only

    Login
    ‌
    ‌

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular Authors

    Genome-wide association study of response to methotrexate in early rheumatoid arthritis patients

    View/Open
    Accepted version (1.133Mb)
    Pagination
    528 - 538
    Publisher
    Springer Nature
    DOI
    10.1038/s41397-018-0025-5
    Journal
    PHARMACOGENOMICS JOURNAL
    ISSN
    1470-269X
    Metadata
    Show full item record
    Abstract
    Methotrexate (MTX) monotherapy is a common first treatment for rheumatoid arthritis (RA), but many patients do not respond adequately. In order to identify genetic predictors of response, we have combined data from two consortia to carry out a genome-wide study of response to MTX in 1424 early RA patients of European ancestry. Clinical endpoints were change from baseline to 6 months after starting treatment in swollen 28-joint count, tender 28-joint count, C-reactive protein and the overall 3-component disease activity score (DAS28). No single nucleotide polymorphism (SNP) reached genome-wide statistical significance for any outcome measure. The strongest evidence for association was with rs168201 in NRG3 (p = 10−7 for change in DAS28). Some support was also seen for association with ZMIZ1, previously highlighted in a study of response to MTX in juvenile idiopathic arthritis. Follow-up in two smaller cohorts of 429 and 177 RA patients did not support these findings, although these cohorts were more heterogeneous.
    Authors
    Taylor, JC; Bongartz, T; Massey, J; Mifsud, B; Spiliopoulou, A; Scott, IC; Wang, J; Morgan, M; Plant, D; Colombo, M
    URI
    https://qmro.qmul.ac.uk/xmlui/handle/123456789/54860
    Collections
    • Clinical Pharmacology [115]
    Licence information
    Author post-prints of subscription articles are subject to Springer Nature re-use terms
    Twitter iconFollow QMUL on Twitter
    Twitter iconFollow QM Research
    Online on twitter
    Facebook iconLike us on Facebook
    • Site Map
    • Privacy and cookies
    • Disclaimer
    • Accessibility
    • Contacts
    • Intranet
    • Current students

    Modern Slavery Statement

    Queen Mary University of London
    Mile End Road
    London E1 4NS
    Tel: +44 (0)20 7882 5555

    © Queen Mary University of London.